Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

HLX3901

Phase 1Small molecule

Shanghai Henlius Biotech

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

SCLCRecruiting

SCLCPhase 1

Recruiting

Timeline

Expected Milestones

Q2 2029

Phase 1Recruiting

SCLC

NCT07416695

Clinical

Trials by Indication[1]

SCLC1 trial

A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 (DLL3 × DLL3 × CD3 × CD28 Tetra-specific Antibody) in Patients With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma

Recruiting· Shanghai Henlius Biotech logo

Shanghai Henlius Biotech·Phase 1·NCT07416695·138 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HLX3901. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HLX3901 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HLX3901. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Henlius Biotech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Shanghai Henlius Biotech

Related News